Protein stability and aggregation in Parkinson's disease

Biochemical Journal

Volumn 413, Issue 1, 2008, Pages 1-13

  Robinson, Philip A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Chaperone; Mitochondrion; Parkinson's disease; Reactive oxygen species (ROS); Ubiquitin

Indexed keywords

BRAIN; ELECTRIC MACHINE INSULATION; HEALTH; INCLUSIONS;

(E ,3E) PROCESS; AGE-RELATED; BREAKDOWN (BD); CELL TOXICITY; CELLULAR STRESSES; CLINICAL SYMPTOMS; DIFFERENTIATED CELLS; DOPAMINE (DPM); DOPAMINERGIC (DA) NEURONS; END POINT (EP); ENVIRONMENTAL FACTORS; FUNDAMENTAL QUESTIONS; INCLUSION FORMATION; LEWY BODIES; MITOCHONDRIAL ACTIVITIES; MITOCHONDRIAL TOXINS; NEURITES; NEURO-DEGENERATIVE DISEASE; PARKINSON'S DISEASE (PD); PROTEIN DAMAGE; PROTEIN PROCESSING; PROTEIN STABILITY; SUBSTANTIA NIGRA;

NEURONS;

ALPHA SYNUCLEIN; AMYLOID; CASEIN KINASE I; CASEIN KINASE II; CHAPERONE; CULLIN; DJ 1 PROTEIN; DOPAMINE; F BOX PROTEIN; G PROTEIN COUPLED RECEPTOR KINASE 5; LEUCINE RICH REPEAT KINASE 2; PARKIN; PHOSPHATASE AND TENSIN HOMOLOGUE DELETED ON CHROMOSOME 10 INDUCED KINASE 1; PROTEASOME; PROTEIN CHIP; PROTEIN SERINE THREONINE KINASE; UBIQUITIN; UBIQUITIN THIOLESTERASE; PROTEIN;

CELL DAMAGE; CELL DIFFERENTIATION; CELL STRESS; CELL SURVIVAL; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; ENDOPLASMIC RETICULUM; ENVIRONMENTAL FACTOR; GENE DUPLICATION; GENE MUTATION; GENETIC ASSOCIATION; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; LEWY BODY; MISSENSE MUTATION; MITOCHONDRION; NEURITE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN STABILITY; REVIEW; SUBSTANTIA NIGRA; UBIQUITINATION; ANIMAL; BRAIN; CELL INCLUSION; CHEMISTRY; GENETICS; METABOLISM; MOUSE; NERVE CELL; PATHOLOGY;

ANIMALS; BRAIN; HUMANS; INCLUSION BODIES; MICE; NEURONS; PARKINSON DISEASE; PROTEINS;

EID: 46249089256     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20080295     Document Type: Review

References (216)

1. Cookson, M. R. (2005) The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 74, 29-52
2. Moore, D. J., West, A. B., Dawson, V. L. and Dawson, T. M. (2005) Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28, 57-87
3. Thomas, B. and Beal, M. F. (2007) Parkinson's disease. Hum. Mol. Genet. 16, R183-R194
4. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R. et al. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047
5. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y. and Shimizu, N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608
6. Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T. et al. (1998) The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452
7. Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K. and Suzuki, T. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25, 302-305
8. Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M. et al. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256-259
9. Le, W., Xu, P., Jankovic, J., Jiang, H., Appel, S. H., Smith, R. G. and Vassilatis, D. K. (2003) Mutations in NR4A2 associated with familial Parkinson disease. Nat. Genet. 33, 85-89
10. Marx, F. P., Holzmann, C., Strauss, K. M., Li, L., Eberhardt, O., Gerhardt, E., Cookson, M. R., Hernandez, D., Farrer, M. J., Kachergus, J. et al. (2003) Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum. Mol. Genet. 12, 1223-1231
11. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R. et al. (2003) α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841
12. Chartier-Harlin, M. C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M. et al. (2004) α-Synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169
13. Paisan-Ruiz, C., Jain, S., Evans, E. W., Gilks, W. P., Simon, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600
14. Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G. et al. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158-1160
15. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B. et al. (2004) Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron 44, 601-607
16. Ramirez, A., Heimbach, A., Gruendemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A. L., Roeper, J. et al. (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 38, 1184-1191
17. McNaught, K. S. P., Belizaire, R., Jenner, P., Olanow, C. W. and Isacson, O. (2002) Selective loss of 20S proteasome α-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci. Lett. 326, 155-158
18. Hinault, M. P., Ben-Zvi, A. and Goloubinoff, P. (2006) Chaperones and proteases: cellular fold-controlling factors of proteins in neurodegenerative diseases and aging. J. Mol. Neurosci. 30, 249-265
19. Gregersen, N., Bross, P., Vang, S. and Christensen, J. H. (2006) Protein misfolding and human disease. Annu. Rev. Gen. Hum. Genet. 7, 103-124
20. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W. H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A. et al. (2000) Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252
21. Feany, M. B. and Bender, W. W. (2000) A Drosophila model of Parkinson's disease. Nature 404, 394-398
22. Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A. and Mucke, L. (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269
23. Auluck, P. K., Chan, H. Y. E., Trojanowski, J. Q., Lee, V. M. Y. and Bonini, N. M. (2002) Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295, 865-868
24. Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q. and Lee, V. M.-Y. (2002) Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 34, 521-533
25. Greene, J. C., Whitworth, A. J., Kuo, I., Andrews, L. A., Feany, M. B. and Pallanck, L. J. (2003) Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl. Acad. Sci. U.S.A. 100, 4078-4083
26. Palacino, J. J., Sagi, D., Goldberg, M. S., Krauss, S., Motz, C., Wacker, M., Klose, J. and Shen, J. (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 279, 18614-18622
27. Periquet, M., Corti, O., Jacquier, S. and Brice, A. (2005) Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function. J. Neurochem. 95, 1259-1276
28. Ved, R., Saha, S., Westlund, B., Perier, C., Burnam, L., Sluder, A., Hoener, M., Rodrigues, C. M. P., Alfonso, A., Steer, C. et al. (2005) Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of α-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J. Biol. Chem. 280, 42655-42668
29. Yang, Y. F., Gehrke, S., Haque, M. E., Imai, Y., Kosek, J., Yang, L. C., Beal, M. F., Nishimura, I., Wakarnatsu, K., Ito, S. et al. (2005) Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc. Natl. Acad. Sci. U.S.A. 102, 13670-13675
30. Clark, I. E., Dodson, M. W., Jiang, C. G., Cao, J. H., Huh, J. R., Seol, J. H., Yoo, S. J., Hay, B. A. and Guo, M. (2006) Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441, 1162-1166
31. Martin, L. J., Pan, Y., Price, A. C., Sterling, W., Copeland, N. G., Jenkins, N. A., Price, D. L. and Lee, M. K. (2006) Parkinson's disease α-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 26, 41-50
32. Wang, D. L., Qian, L., Xiong, H., Liu, J. D., Neckameyer, W. S., Oldham, S., Xia, K., Wang, J. Z., Bodmer, R. and Zhang, Z. H. (2006) Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila. Proc. Natl. Acad. Sci. U.S.A. 103, 13520-13525
33. Yang, Y. F., Gehrke, S., Imai, Y., Huang, Z. N., Ouyang, Y., Wang, J. W., Yang, L. C., Beal, M. F., Vogel, H. and Lu, B. W. (2006) Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused inactivation of Drosophila Pink1 is rescued by Parkin. Proc. Natl. Acad. Sci. U.S.A. 103, 10793-10798
34. Li, W. W., Yang, R., Guo, J. C., Ren, H. M., Zha, X. L., Cheng, J. S. and Cai, D. F. (2007) Localization of α-synuclein to mitochondria within midbrain of mice. NeuroReport 18, 1543-1546
35. Outeiro, T. F., Kontopoulos, E., Altmann, S. M., Kufareva, I., Strathearn, K. E., Amore, A. M., Volk, C. B., Maxwell, M. M., Rochet, J. C., McLean, P. J. et al. (2007) Sirtuin 2 inhibitors rescue α-synuclein- mediated toxicity in models of Parkinson's disease. Science 317, 516-519
36. Stichel, C. C., Zhu, X.-R., Bader, V., Linnartz, B., Schmidt, S. and Lubbert, H. (2007) Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. Hum. Mol. Genet. 16, 2377-2393
37. Wakamatsu, M., Ishii, A., Ukai, Y., Sakagami, J., Iwata, S., Ono, M., Matsumoto, K., Nakamura, A., Tada, N., Kobayashi, K. et al. (2007) Accumulation of phosphorylated α-synuclein in dopaminergic neurons of transgenic mice that express human α-synuclein. J. Neurosci. Res. 85, 1819-1825
38. McNaught, K. S., Mytilineou, C., Jnobaptiste, R., Yabut, J., Shashidharan, P., Jenner, P. and Olanow, C. W. (2002) Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem. 81, 301-306
39. Ardley, H. C., Scott, G. B., Rose, S. A., Tan, N. G. S., Markham, A. F. and Robinson, P. A. (2003) Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin. Mol. Biol. Cell 14, 4541-4556
40. Lindersson, E., Beedholm, R., Hojrup, P., Moos, T., Gai, W. P., Hendil, K. B. and Jensen, P. H. (2004) Proteasomal inhibition by α-synuclein filaments and oligomers. J. Biol. Chem. 279, 12924-12934
41. Tanaka, M., Kim, Y. M., Lee, G., Junn, E., Iwatsubo, T. and Mouradian, M. M. (2004) Aggresomes formed by α-synuclein and synphilin-1 are cytoprotective. J. Biol. Chem. 279, 4625-4631
42. Petit, A., Kawarai, T., Paitel, E., Sanjo, N., Maj, M., Scheid, M., Chen, F. S., Gu, Y. J., Hasegawa, H., Salehi-Rad, S. et al. (2005) Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J. Biol. Chem. 280, 34025-34032
43. Smith, W. W., Jiang, H. B., Pei, Z., Tanaka, Y., Morita, H., Sawa, A., Dawson, V. L., Dawson, T. M. and Ross, C. A. (2005) Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant α-synuclein- induced toxicity. Hum. Mol. Genet. 14, 3801-3811
44. Smith, W. W., Margolis, R. L., Li, X. J., Troncoso, J. C., Lee, M. K., Dawson, V. L., Dawson, T. M., Iwatsubo, T. and Ross, C. A. (2005) α-Synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci. 25, 5544-5552
45. Kitamura, Y., Sanada, H., Kakimura, J., Ishida, Y., Shimohama, S. and Taniguchi, T. (2001) Decrease of tyrosine hydroxylase-, α-synuclein- and parkin-expressing neurons in the substantia nigra of MPTP-treated C57BL/6N mice. Biog. Amines 16, 127-136
46. Fornai, F., Schluter, O. M., Lenzi, P., Gesi, M., Ruffoli, R., Ferrucci, M., Lazzeri, G., Busceti, C. L., Pontarelli, F., Battaglia, G. et al. (2005) Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and α-synuclein. Proc. Natl. Acad. Sci. U.S.A. 102, 3413-3418
47. Klivenyi, P., Siwek, D., Gardian, G., Yang, L. H., Starkov, A., Cleren, C., Ferrante, R. J., Kowall, N. W., Abellovich, A. and Beal, M. F. (2006) Mice lacking α-synuclein are resistant to mitochondrial toxins. Neurobiol. Dis. 21, 541-548
48. Hirokawa, N. and Takemura, R. (2005) Molecular motors and mechanisms of directional transport in neurons. Nat. Rev. Neurosci. 6, 201-214
49. Ly, C. V. and Verstreken, P. (2006) Mitochondria at the synapse. Neuroscientist 12, 291-299
50. Orr, A. L., Li, S. H., Wang, C. E., Li, H., Wang, J. J., Rong, J., Xu, X. S., Mastroberardino, P. G., Greenamyre, J. T. and Li, X. J. (2008) N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci. 28, 2783-2792
51. Ferreirinha, F., Quattrini, A., Pirozzi, M., Valsecchi, V., Dina, G., Broccoli, V., Auricchio, A., Piemonte, F., Tozzi, G., Gaeta, L. et al. (2004) Axonal degeneration in paraplegin-deficient mice is associated with abnormal mitochondria and impairment of axonal transport. J. Clin. Invest. 113, 231-242
52. Rugarli, E. I. and Langer, T. (2006) Translating m-AAA protease function in mitochondria to hereditary spastic paraplegia. Trends Mol. Med. 12, 262-269
53. Shults, C. W. (2006) Lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 103, 1661-1668
54. Iwatsubo, T. (2007) Pathological biochemistry of α-synucleinopathy. Neuropathology 27, 474-478
55. Spillantini, M. G. and Goedert, M. (2000) The α-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann. N.Y. Acad. Sci. 920, 16-27
56. Spillantini, M. G., Schmidt, M. L., Lee, V. M. Y., Trojanowski, J. Q., Jakes, R. and Goedert, M. (1997) α-Synuclein in Lewy bodies. Nature 388, 839-840
57. Lundvig, D., Lindersson, E. and Jensen, P. H. (2005) Pathogenic effects of α-synuclein aggregation. Mol. Brain Res. 134, 3-17
58. Kramer, M. L. and Schulz-Schaeffer, W. J. (2007) Presynaptic α-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J. Neurosci. 27, 1405-1410
59. Lee, H. J. and Lee, S. J. (2002) Characterization of cytoplasmic α-synuclein aggregates: fibril formation is tightly linked to the inclusion-forming process in cells. J. Biol. Chem. 277, 48976-48983
60. Kopito, R. R. (2000) Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 10, 524-530
61. Davidson, W. S., Jonas, A., Clayton, D. F. and George, J. M. (1998) Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443-9449
62. Volles, M. J. and Lansbury, Jr, P. T. (2007) Relationships between the sequence of α-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J. Mol. Biol. 366, 1510-1522
63. Jo, E. J., McLaurin, J., Yip, C. M., St George-Hyslop, P. and Fraser, P. E. (2000) α-Synuclein membrane interactions and lipid specificity. J. Biol. Chem. 275, 34328-34334
64. Sharon, R., Bar-Joseph, I., Frosch, M. P., Walsh, D. M., Hamilton, J. A. and Selkoe, D. J. (2003) The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583-595
65. Chandra, S., Gallardo, G., Fernandez-Chacon, R., Schluter, O. M. and Sudhof, T. C. (2005) α-Synuclein cooperates with CSPα in preventing neurodegeneration. Cell 123, 383-396
66. Zhang, Y., Gao, J., Chung, K. K. K., Huang, H., Dawson, V. L. and Dawson, T. M. (2000) Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. U.S.A. 97, 13354-13359
67. Schlossmacher, M. G., Frosch, M. P., Gai, W., P., Medina, M., Sharma, N., Forno, L., Ochiishi, T., Shimura, H., Sharon, R., Hattori, N. et al. (2002) Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am. J. Pathol. 160, 1655-1667
68. Zhou, Y., Gu, G. Y., Goodlett, D. R., Zhang, T., Pan, C., Montine, T. J., Montine, K. S., Aebersold, R. H. and Zhang, J. (2004) Analysis of α-synuclein-associated proteins by quantitative proteomics. J. Biol. Chem. 279, 39155-39164
69. Jin, J. H., Li, G. J., Davis, J., Zhu, D., Wang, Y., Pan, C. and Zhang, J. (2007) Identification of novel proteins associated with both α-synuclein and DJ-1. Mol. Cell. Proteomics 6, 845-859
70. Meulener, M. C., Graves, C. L., Sampathu, D. M., Armstrong-Gold, C. E., Bonini, N. M. and Giasson, B. I. (2005) DJ-1 is present in a large molecular complex in human brain tissue and interacts with α-synuclein. J. Neurochem. 93, 1524-1532
71. Shendelman, S., Jonason, A., Martinat, C., Leete, T. and Abeliovich, A. (2004) DJ-1 is a redox-dependent molecular chaperone that inhibits α-synuclein aggregate formation. PLoS Biol. 2, 1764-1773
72. Zhou, W. B. and Freed, C. R. (2005) DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T α-synuclein toxicity. J. Biol. Chem. 280, 43150-43158
73. Zhou, W. B., Zhu, M., Wilson, M. A., Petsko, G. A. and Fink, A. L. (2006) The oxidation state of DJ-1 regulates its chaperone activity toward α-synuclein. J. Mol. Biol. 356, 1036-1048
74. Willingham, S., Outeiro, T. F., DeVit, M. J., Lindquist, S. L. and Muchowski, P. J. (2003) Yeast genes that enhance the toxicity of a mutant huntingtin fragment or α-synuclein. Science 302, 1769-1772
75. Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K. and Iwatsubo, T. (2002) α-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160-164
76. Hasegawa, M., Fujiwara, H., Nonaka, T., Wakabayashi, K., Takahashi, H., Lee, V. M. Y., Trojanowski, J. Q., Mann, D. and Iwatsubo, T. (2002) Phosphorylated α-synuclein is ubiquitinated in α-synucleinopathy lesions. J. Biol. Chem. 277, 49071-49076
77. Anderson, J. P., Walker, D. E., Goldstein, J. M., de Laat, R., Banducci, K., Caccavello, R. J., Barbour, R., Huang, J. P., Kling, K., Lee, M. et al. (2006) Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739-29752
78. Trimmer, P. A., Keeney, P. M., Borland, M. K., Simon, F. A., Almeida, J., Swerdlow, R. H., Parks, J. P., Parker, W. D. and Bennett, J. P. (2004) Mitochondrial abnormalities in cybrid cell models of sporadic Alzheimer's disease worsen with passage in culture. Neurobiol. Dis. 15, 29-39
79. Shults, C. W., Barrett, J. M. and Fontaine, D. (2006) α-Synuclein from platelets is not phosphorylated at serine 129 in Parkinson's disease and multiple system atrophy. Neurosci. Lett. 405, 223-225
80. Chen, L. and Feany, M. B. (2005) α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 8, 657-663
81. Tofaris, G. K., Reitbock, P. G., Humby, T., Lambourne, S. L., O'Connell, M., Ghetti, B., Gossage, H., Emson, P. C., Wilkinson, L. S., Goedert, M. and Spillantini, M. G. (2006) Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human α-synuclein (1-120): implications for Lewy body disorders. J. Neurosci. 26, 3942-3950
82. Okochi, M., Walter, J., Koyama, A., Nakajo, S., Baba, M., Iwatsubo, T., Meijer, L., Kahle, P. J. and Haass, C. (2000) Constitutive phosphorylation of the Parkinson's disease associated α-synuclein. J. Biol. Chem. 275, 390-397
83. Arawaka, S., Wada, M., Goto, S., Karube, H., Sakamoto, M., Ren, C. H., Koyama, S., Nagasawa, H., Kimura, H., Kawanami, T. et al. (2006) The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease. J. Neurosci. 26, 9227-9238
84. 129 of human α-synuclein: implication for α-synucleinopathies. FEBS Lett. 581, 4711-4717
85. Takahashi, M., Ko, L. W., Kulathingal, J., Jiang, P. Z., Sevlever, D. and Yen, S. H. C. (2007) Oxidative stress-induced phosphorylation, degradation and aggregation of α-synuclein are linked to upregulated CK2 and cathepsin D. Eur. J. Neurosci. 26, 863-874
86. Liu, C. W., Corboy, M. J., DeMartino, G. N. and Thomas, P. J. (2003) Endoproteolytic activity of the proteasome. Science 299, 408-411
87. Liu, C. W., Giasson, B. I., Lewis, K. A., Lee, V. M., DeMartino, G. N. and Thomas, P. J. (2005) A precipitating role for truncated α-synuclein and the proteasome in α-synuclein aggregation: implications for pathogenesis of Parkinson disease. J. Biol. Chem. 280, 22670-22678
88. Dufty, B. M., Warner, L. R., Hou, S. T., Jiang, S. X., Gomez-Isla, T., Leenhouts, K. M., Oxford, J. T., Feany, M. B., Masliah, E. and Rohn, T. T. (2007) Calpain-cleavage of α-synuclein: connecting proteolytic processing to disease-linked aggregation. Am. J. Pathol. 170, 1725-1738
89. Crocker, S. J., Smith, P. D., Jackson-Lewis, V., Lamba, W. R., Hayley, S. P., Grimm, E., Callaghan, S. M., Slack, R. S., Melloni, E., Przedborski, S. et al. (2003) Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J. Neurosci. 23, 4081-4091
90. Kim, S. J., Sung, J. Y., Um, J. W., Hattori, N., Mizuno, Y., Tanaka, K., Paik, S. R., Kim, J. and Chung, K. C. (2003) Parkin cleaves intracellular α-synuclein inclusions via the activation of calpain. J. Biol. Chem. 278, 41890-41899
91. Chen, M. H. J., Yap, Y. W., Choy, M. S., Koh, C. H. V., Seet, S. J., Duan, W., Whiteman, M. and Cheung, N. S. (2006) Early induction of calpains in rotenone-mediated neuronal apoptosis. Neurosci. Lett. 397, 69-73
92. Kontopoulos, E., Parvin, J. D. and Feany, M. B. (2006) α-Synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet. 15, 3012-3023
93. Kawaguchi, Y., Kovacs, J. J., McLaurin, A., Vance, J. M., Ito, A. and Yao, T. P. (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115, 727-738
94. Muqit, M. M. K., Abou-Sleiman, P. M., Saurin, A. T., Harvey, K., Gandhi, S., Deas, E., Eaton, S., Smith, M. D. P., Venner, K., Matilla, A. et al. (2006) Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J. Neurochem. 98, 156-169
95. Sim, C., H., Lio, D. S. S., Mok, S. S., Masters, C. L., Hill, A. F., Culvenor, J. G. and Cheng, H. C. (2006) C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum. Mol. Genet. 15, 3251-3262
96. Beilina, A., Van Der Brug, M., Ahmad, R., Kesavapanyt, S., Miller, D. W., Petsko, G. A. and Cookson, M. R. (2005) Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc. Natl. Acad. Sci. U.S.A. 102, 5703-5708
97. Welchman, R. L., Gordon, C. and Mayer, R. J. (2005) Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat. Rev. Mol. Cell Biol. 6, 599-609
98. Kerscher, O., Felberbaum, R. and Hochstrasser, M. (2006) Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 22, 159-180
99. Robinson, P. A. and Ardley, H. C. (2004) Ubiquitin-protein ligases: novel therapeutic targets?. Curr. Protein Pept. Sci. 5, 163-176
100. Deshaies, R. J. (1999) SCF and cullin/RING H2-based ubiquitin ligases. Annu. Rev. Cell Dev. Biol. 15, 435-467
101. Castro, A., Bernis, C., Vigneron, S., Labbe, J. C. and Lorca, T. (2005) The anaphase-promoting complex: a key factor in the regulation of cell cycle. Oncogene 24, 314-325
102. Koegl, M., Hoppe, T., Schlenker, S., Ulrich, H. D., Mayer, T. U. and Jentsch, S. (1999) A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 96, 635-644
103. Li, W., Tu, D. Q., Brunger, A. T. and Ye, Y. H. (2007) A ubiquitin ligase transfers preformed polyubiquitin chains from a conjugating enzyme to a substrate. Nature 446, 333-337
104. Chen, L., Thiruchelvam, M. J., Madura, K. and Richfield, E. K. (2006) Proteasome dysfunction in aged human α-synuclein transgenic mice. Neurobiol. Dis. 23, 120-126
105. Sun, F., Anantharam, V., Zhang, D., Latchoumycandane, C., Kanthasamy, A. and Kanthasamy, A. G. (2006) Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models. Neurotoxicology 27, 807-815
106. Bennett, E. J., Shaler, T. A., Woodman, B., Ryu, K. Y., Zaitseva, T. S., Becker, C. H., Bates, G. P., Schulman, H. and Kopito, R. R. (2007) Global changes to the ubiquitin system in Huntington's disease. Nature 448, 704-711
107. Healy, D. G., Abou-Sleiman, P. M., Casas, J. P., Ahmadi, K. R., Lynch, T., Gandhi, S., Muqit, M. M. K., Foltynie, T., Barker, R., Bhatia, K. P. et al. (2006) UCHL-1 is not a Parkinson's disease susceptibility gene. Ann. Neurol. 59, 627-633
108. Moore, D. J., Zhang, L., Troncoso, J., Lee, M. K., Hattori, N., Mizuno, Y., Dawson, T. M. and Dawson, V. L. (2005) Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum. Mol. Genet. 14, 71-84
109. Goldberg, M. S., Fleming, S. M., Palacino, J. J., Cepeda, C., Lam, H. A., Bhatnagar, A., Meloni, E. G., Wu, N. P., Ackerson, L. C., Klapstein, G. J. et al. (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 278, 43628-43635
110. Itier, J. M., Ibanez, P., Mena, M. A., Abbas, N., Cohen-Salmon, C., Bohme, G. A., Laville, M., Pratt, J., Corti, O., Pradier, L. et al. (2003) Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Genet. 12, 2277-2291
111. Ko, H. S., von Coelln, R., Sriram, S. R., Kim, S. W., Chung, K. K. K., Pletnikova, O., Troncoso, J., Johnson, B., Saffary, R., Goh, E. L. et al. (2005) Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J. Neurosci. 25, 7968-7978
112. Chung, K. K. K., Zhang, Y., Lim, K. L., Tanaka, Y., Huang, H., Gao, J., Ross, C. A., Dawson, V. L. and Dawson, T. M. (2001) Parkin ubiquitinates the α-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med. 7, 1144-1150
113. Imai, Y., Soda, M., Inoue, H., Hattori, N., Mizuno, Y. and Takahashi, R. (2001) An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin. Cell 105, 891-902
114. Shimura, H., Schlossmacher, M. C., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K. S. and Selkoe, D. J. (2001) Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263-269
115. Choi, P., Snyder, H., Petrucelli, L., Theisler, C., Chong, M., Zhang, Y., Lim, K., Chung, K. K. K., Kehoe, K., D'Adamio, L. et al. (2003) SEPT5_v2 is a parkin-binding protein. Mol. Brain Res. 117, 179-189
116. Son, J. H., Kawamata, H., Yoo, M. S., Kim, D. J., Lee, Y. K., Kim, S. Y., Dawson, T. M., Zhang, H., Sulzer, D., Yang, L. C. et al. (2005) Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons. J. Neurochem. 94, 1040-1053
117. Ko, H. S., Kim, S. W., Sriram, S. R., Dawson, V. L. and Dawson, T. M. (2006) Identification of far upstream element-binding protein-1 as an authentic parkin substrate. J. Biol. Chem. 281, 16193-16196
118. Joch, M., Ase, A. R., Chen, C. X. Q., MacDonald, P. A., Kontogiannea, M., Corera, A. T., Brice, A., Seguela, P. and Fon, E. A. (2007) Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels. Mol. Biol. Cell 18, 3105-3118
119. Gosink, M. M. and Vierstra, R. D. (1995) Redirecting the specificity of ubiquitination by modifying ubiquitin-conjugating enzymes. Proc. Natl. Acad. Sci. U.S.A. 92, 9117-9121
120. Yamasaki, S., Yagishita, N., Sasaki, T., Nakazawa, M., Kato, Y., Yamadera, T., Bae, E., Toriyama, S., Ikeda, R., Zhang, L. et al. (2007) Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. EMBO J. 26, 113-122
121. Bandopadhyay, R., Kingsbury, A. E., Muqit, M. M., Harvey, K., Reid, A. R., Kilford, L., Engelender, S., Schlossmacher, M. G., Wood, N. W., Latchman, D. S. et al. (2005) Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition. Neurobiol. Dis. 20, 401-411
122. Liani, E., Eyal, A., Avraham, E., Shemer, R., Szargel, R., Berg, D., Bornemann, A., Riess, O., Ross, C. A., Rott, R. and Engelender, S. (2004) Ubiquitylation of synphilin-1 and α-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 101, 5500-5505
123. Lim, K. L., Dawson, V. L. and Dawson, T. M. (2006) Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson's and other conformational diseases?. Neurobiol. Aging 27, 524-529
124. Hampe, C., Ardila-Osorio, H., Fournier, M., Brice, A. and Corti, O. (2006) Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum. Mol. Genet. 15, 2059-2075
125. Lim, M. K., Kawamura, T., Ohsawa, Y., Ohtsubo, M., Asakawa, S., Takayanagi, A. and Shimizu, N. (2007) Parkin interacts with LIM Kinase 1 and reduces its cofilin-phosphorylation activity via ubiquitination. Exp. Cell Res. 313, 2858-2874
126. Corti, O., Hampe, C., Koutnikova, H., Darios, F., Jacquier, S., Prigent, A., Robinson, J. C., Pradier, L., Ruberg, M., Mirande, M. et al. (2003) The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum. Mol. Genet. 12, 1427-1437
127. Cookson, M. R., Lockhart, P. J., O'Farrell, C., Schlossmacher, M. and Farrer, M. J. (2003) RING finger 1 mutations in Parkin produce altered localization of the protein. Hum. Mol. Genet. 12, 2957-2965
128. Chung, K. K. K., Thomas, B., Li, X. J., Pletnikova, O., Troncoso, J. C., Marsh, L., Dawson, V. L. and Dawson, T. M. (2004) S-nitrosylation of Parkin regulates ubiquitination and compromises Parkin's protective function. Science 304, 1328-1331
129. Chung, K. K. K., Dawson, T. M. and Dawson, V. L. (2005) Nitric oxide, S-nitrosylation and neurodegeneration. Cell. Mol. Biol. 51, 247-254
130. LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G. and Selkoe, D. J. (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11, 1214-1221
131. Wang, C., Ko, H. S., Thomas, B., Tsang, F., Chew, K. C. M., Tay, S. P., Ho, M. W. L., Lim, T. M., Soong, T. W., Pletnikova, O. et al. (2005) Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum. Mol. Genet. 14, 3885-3897
132. Wang, C., Tan, J. M. M., Ho, M. W. L., Zaiden, N., Wong, S. H., Chew, C. L. C., Eng, P. W., Lim, T. M., Dawson, T. M. and Lim, K. L. (2005) Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations. J. Neurochem. 93, 422-431
133. Avraham, E., Rott, R., Liani, E., Szargel, R. and Engelender, S. (2007) Phosphorylation of parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation. J. Biol. Chem. 282, 12842-12850
134. Wong, E. S. P., Tan, J. M. M., Wang, C., Zhang, Z. S., Tay, S. P., Zaiden, N., Ko, H. S., Dawson, V. L., Dawson, T. M. and Lim, K. L. (2007) Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations. J. Biol. Chem. 282, 12310-12318
135. Junn, E., Lee, S. S., Suhr, U. T. and Mouradian, M. M. (2002) Parkin accumulation in aggresomes due to proteasome impairment. J. Biol. Chem. 277, 47870-47877
136. Moynihan, T. P., Ardley, H. C., Nuber, U., Rose, S. A., Jones, P. F., Markham, A. F., Scheffner, M. and Robinson, P. A. (1999) The ubiquitin-conjugating enzymes UbcH7 and UbcH8 interact with RING finger/IBR motif-containing domains of HHARI and H7-AP1. J. Biol. Chem. 274, 30963-30968
137. Ardley, H. C., Tan, N. G. S., Rose, S. A., Markham, A. F. and Robinson, P. A. (2001) Features of the Parkin/ariadne-like ubiquitin ligase, HHARI, that regulate its interaction with the ubiquitin-conjugating enzyme, UbcH7. J. Biol. Chem. 276, 19640-19647
138. Zhong, L., Tan, Y., Zhou, A., Yu, Q. M. and Zhou, J. H. (2005) RING finger ubiquitin-protein isopeptide ligase Nrdp1/FLRF regulates parkin stability and activity. J. Biol. Chem. 280, 9425-9430
139. Kahns, S., Lykkobo, S., Jakobsen, L. D., Nielsen, M. S. and Jensen, P. H. (2002) Caspase-mediated parkin cleavage in apoptotic cell death. J. Biol. Chem. 277, 15303-15308
140. Romisch, K. (2005) Endoplasmic reticulum-associated degradation. Annu. Rev. Cell Dev. Biol. 21, 435-456
141. Ismail, N. and Ng, D. T. W. (2006) Have you HRD?. Understanding ERAD is DOAble! Cell 126, 237-239
142. Kawaguchi, S. and Ng, D. T. W. (2007) Snapshot: ER-associated protein degradation pathways. Cell 129, 1230
143. Schroder, M. and Kaufman, R. J. (2005) The mammalian unfolded protein response. Annu. Rev. Biochem. 74, 739-789
144. Yang, Y. F., Nishimura, I., Imai, Y., Takahashi, R. and Lu, B. W. (2003) Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37, 911-924
145. Murakami, T., Shoji, M., Imai, Y., Inoue, H., Kawarabayashi, T., Matsubara, E., Harigaya, Y., Sasaki, A., Takahashi, R. and Abe, K. (2004) Pael-R is accumulated in Lewy bodies of Parkinson's disease. Ann. Neurol. 55, 439-442
146. Kitao, Y., Imai, Y., Ozawa, K., Kataoka, A., Ikeda, T., Soda, M., Nakimawa, K., Kiyama, H., Stern, D. M., Hori, O. et al. (2007) Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation. Hum. Mol. Genet. 16, 50-60
147. Carvalho, P., Goder, V. and Rapoport, T. A. (2006) Distinct ubiquitin-ligase complexes define convergent pathways for the degradation of ER
148. Zhong, X. Y., Shen, Y. X., Ballar, P., Apostolou, A., Agami, R. and Fang, S. Y. (2004) AAA ATPase p97/valosin-containing protein interacts with gp78, a ubiquitin ligase for endoplasmic reticulum-associated degradation. J. Biol. Chem. 279, 45676-45684
149. Fang, S. Y., Ferrone, M., Yang, C. H., Jensen, J. P., Tiwari, S. and Weissman, A. M. (2001) The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum. Proc. Natl. Acad. Sci. U.S.A. 98, 14422-14427
150. Amano, T., Yamasaki, S., Yagishita, N., Tsuchimochi, K., Shin, H., Kawahara, K.-i., Aratani, S., Fujita, H., Zhang, L., Ikeda, R. et al. (2003) Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy. Genes Dev. 17, 2436-2449
151. Neutzner, A., Youle, R. J. and Karbowski, M. (2007) Outer mitochondrial membrane protein degradation by the proteasome. Mitochondrial Biology: New Perspectives (Chadwick, D. J. and Goode, J., eds), pp. 4-14, John Wiley & Sons, Chichester
152. Christianson, J. C., Shaler, T. A., Tyler, R. E. and Kopito, R. R. (2008) OS-9 and GRP94 deliver mutant α1-antitrypsin to the Hrd1-SEL1L ubiquitin ligase complex for ERAD. Nat. Cell Biol. 10, 272-282
153. Cooper, A. A., Gitler, A. D., Cashikar, A., Haynes, C. M., Hill, K. J., Bhullar, B., Liu, K. N., Xu, K. X., Strathearn, K. E., Liu, F. et al. (2006) α-Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313, 324-328
154. Zourlidou, A., Smith, M. D. P. and Latchman, D. S. (2004) HSP27 but not HSP70 has a potent protective effect against α-synuclein-induced cell death in mammalian neuronal cells. J. Neurochem. 88, 1439-1448
155. Klucken, J., Shin, Y., Masliah, E., Hyman, B. T. and McLean, P. J. (2004) Hsp70 reduces α-synuclein aggregation and toxicity. J. Biol. Chem. 279, 25497-25502
156. Ballinger, C. A., Connell, P., Wu, Y. X., Hu, Z. Y., Thompson, L. J., Yin, L. Y. and Patterson, C. (1999) Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol. Cell. Biol. 19, 4535-4545
157. Murata, S., Chiba, T. and Tanaka, K. (2003) CHIP: a quality-control E3 ligase collaborating with molecular chaperones. Int. J. Biochem. Cell Biol. 35, 572-578
158. Rosser, M. F. N., Washburn, E., Muchowski, P. J., Patterson, C. and Cyr, D. M. (2007) Chaperone functions of the E3 ubiquitin ligase CHIP. J. Biol. Chem. 282, 22267-22277
159. Petrucelli, L., Dickson, D., Kehoe, K., Taylor, J., Snyder, H., Grover, A., De Lucia, M., McGowan, E., Lewis, J., Prihar, G. et al. (2004) CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 13, 703-714
160. Shin, Y. G., Klucken, J., Patterson, C., Hyman, B. T. and McLean, P. J. (2005) The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates α-synuclein degradation decisions between proteasomal and lysosomal pathways. J. Biol. Chem. 280, 23727-23734
161. Jiang, J. H., Ballinger, C. A., Wu, Y. X., Dai, Q., Cyr, D. M., Hohfeld, J. and Patterson, C. (2001) CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation. J. Biol. Chem. 276, 42938-42944
162. Murata, S., Minami, Y., Minami, M., Chiba, T. and Tanaka, K. (2001) CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein. EMBO Rep. 2, 1133-1138
163. Kampinga, H. H., Kanon, B., Salomons, F. A., Kabakov, A. E. and Patterson, C. (2003) Overexpression of the cochaperone CHIP enhances Hsp70-dependent folding activity in mammalian cells. Mol. Cell. Biol. 23, 4948-4958
164. Alberti, S., Bohse, K., Arndt, V., Schmitz, A. and Hohfeld, J. (2004) The cochaperone HspBP1 inhibits the CHIP ubiquitin ligase and stimulates the maturation of the cystic fibrosis transmembrane conductance regulator. Mol. Biol. Cell 15, 4003-4010
165. Arndt, V., Daniel, C., Nastainczyk, W., Alberti, S. and Hohfeld, J. (2005) BAG-2 acts as an inhibitor of the chaperone-associated ubiquitin ligase CHIP. Mol. Biol. Cell 16, 5891-5900
166. Alberti, S., Esser, C. and Hohfeld, J. (2003) BAG-1: a nucleotide exchange factor of Hsc70 with multiple cellular functions. Cell Stress Chaperones 8, 225-231
167. Pirkkala, L., Alastalo, T. P., Zuo, X. X., Benjamin, I. J. and Sistonen, L. (2000) Disruption of heat shock factor 1 reveals an essential role in the ubiquitin proteolytic pathway. Mol. Cell. Biol. 20, 2670-2675
168. Dai, Q., Zhang, C. L., Wu, Y. X., McDonough, H., Whaley, R. A., Godfrey, V., Li, H. H., Madamanchi, N., Xu, W., Neckers, L. et al. (2003) CHIP activates HSF1 and confers protection against apoptosis and cellular stress. EMBO J. 22, 5446-5458
169. Qian, S. B., McDonough, H., Boellmann, F., Cyr, D. M. and Patterson, C. (2006) CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70. Nature 440, 551-555
170. Imai, Y., Soda, M., Hatakeyama, S., Akagi, T., Hashikawa, T., Nakayama, K. and Takahashi, R. (2002) CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol. Cell 10, 55-67
171. Takahashi, R. and Imai, Y. (2003) Pael receptor, endoplasmic reticulum stress, and Parkinson's disease. J. Neurol. 250, 25-29
172. Abou-Sleiman, P. M., Healy, D. G., Quinn, N., Lees, A. J. and Wood, N. W. (2003) The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann. Neurol. 54, 283-286
173. Hague, S., Rogaeva, E., Hernandez, D., Gulick, C., Singleton, A., Hanson, M., Johnson, J., Weiser, R., Gallardo, M., Ravina, B. et al. (2003) Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann. Neurol. 54, 271-274
174. Canet-Aviles, R. M., Wilson, M. A., Miller, D. W., Ahmad, R., McLendon, C., Bandyopadhyay, S., Baptista, M. J., Ringe, D., Petsko, G. A. and Cookson, M. R. (2004) The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl. Acad. Sci. U.S.A. 101, 9103-9108
175. Chen, L. N., Cagniard, B., Mathews, T., Jones, S., Koh, H. C., Ding, Y. M., Carvey, P. M., Ling, Z. D., Kang, U. J. and Zhuang, X. X. (2005) Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J. Biol. Chem. 280, 21418-21426
176. Goldberg, M. S., Pisani, A., Haburcak, M., Vortherms, T. A., Kitada, T., Costa, C., Tong, Y., Martella, G., Tscherter, A., Martins, A. et al. (2005) Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45, 489-496
177. Menzies, F. M., Yenisetti, S. C. and Min, K. T. (2005) Roles of Drosophila DJ-1 in survival of dopaminergic neurons and oxidative stress. Curr. Biol. 15, 1578-1582
178. Park, J., Kim, S. Y., Cha, G. H., Lee, S. B., Kim, S. and Chung, J. (2005) Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction. Gene 361, 133-139
179. Zhang, L., Shimoji, M., Thomas, B., Moore, D. J., Yu, S. W., Marupudi, N. I., Torp, R., Torgner, I. A., Ottersen, O. P., Dawson, T. M. and Dawson, V. L. (2005) Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum. Mol. Genet. 14, 2063-2073
180. Inden, M., Taira, T., Kitamura, Y., Yanagida, T., Tsuchiya, D., Takata, K., Yanagisawa, D., Nishimura, K., Taniguchi, T., Kiso, Y. et al. (2006) PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model. Neurobiol. Dis. 24, 144-158
181. Meulener, M. C., Xu, K. X., Thompson, L., Ischiropoulos, H. and Bonini, N. M. (2006) Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging. Proc. Natl. Acad. Sci. U.S.A. 103, 12517-12522
182. Macedo, M. G., Anar, B., Bronner, I. F., Cannella, M., Squitieri, F., Bonifati, V., Hoogeveen, A., Heutink, P. and Rizzu, P. (2003) The DJ-1(L166P) mutant protein associated with early onset Parkinson's disease is unstable and forms higher-order protein complexes. Hum. Mol. Genet. 12, 2807-2816
183. Miller, D. W., Ahmad, R., Hague, S., Baptista, M. J., Canet-Aviles, R., McLendon, C., Carter, D. M., Zhu, P. P., Stadler, J., Chandran, J. et al. (2003) L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J. Biol. Chem. 278, 36588-36595
184. Moore, D. J., Zhang, L., Dawson, T. M. and Dawson, V. L. (2003) A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. J. Neurochem. 87, 1558-1567
185. Blackinton, J., Ahmad, R., Miller, D. W., van der Brug, M. P., Canet-Aviles, R. M., Hague, S. M., Kaleem, M. and Cookson, M. R. (2005) Effects of DJ-1 mutations and polymorphisms on protein stability and subcellular localization. Mol. Brain Res. 134, 76-83
186. Ooe, H., Maita, C., Maita, H., Iguchi-Ariga, S. M. M. and Ariga, H. (2006) Specific cleavage of DJ-1 under an oxidative condition. Neurosci. Lett. 406, 165-168
187. Shinbo, Y., Niki, T., Taira, T., Ooe, H., Takahashi-Niki, K., Maita, C., Seino, C., Iguchi-Ariga, S. M. M. and Ariga, H. (2006) Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities. Cell Death Differ. 13, 96-108
188. Clements, C. M., McNally, R. S., Conti, B. J., Mak, T. W. and Ting, J. P. Y. (2006) DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc. Natl. Acad. Sci. U.S.A. 103, 15091-15096
189. Kobayashi, A., Kang, M. I., Watai, Y., Tong, K. I., Shibata, T., Uchida, K. and Yamamoto, M. (2006) Oxidative and electophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol. Cell. Biol. 26, 221-229
190. Smith, W. L. W., Pei, Z., Jiang, H. B., Dawson, V. L., Dawson, T. M. and Ross, C. A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9, 1231-1233
191. Ito, G., Okai, T., Fujino, G., Takeda, K., Ichijo, H., Katada, T. and Iwatsubo, T. (2007) GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46, 1380-1388
192. Gloeckner, C. J., Kinkl, N., Schumacher, A., Braun, R. J., O'Neill, E., Meitinger, T., Kolch, W., Prokisch, H. and Ueffing, M. (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15, 223-232
193. MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K. and Abeliovich, A. (2006) The familial parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587-593
194. West, A. B., Moore, D. J., Choi, C., Andrabi, S. A., Li, X. J., Dikeman, D., Biskup, S., Zhang, Z., Lim, K. L., Dawson, V. L. and Dawson, T. M. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16, 223-232
195. Smith, W. W., Pei, Z., Jiang, H. B., Moore, D. J., Liang, Y. D., West, A. B., Dawson, V. L., Dawson, T. M. and Ross, C. A. (2005) Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. U.S.A. 102, 18676-18681
196. Biskup, S., Moore, D. J., Celsi, F., Higashi, S., West, A. B., Andrabi, S. A., Kurkinen, K., Yu, S. W., Savitt, J. M., Waldvogel, H. J. et al. (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 60, 557-569
197. Hatano, T., Kubo, S., Imai, S., Maeda, M., Ishikawa, K., Mizuno, Y. and Hattori, N. (2007) Leucine-rich repeat kinase 2 associates with lipid rafts. Hum. Mol. Genet. 16, 678-690
198. Güngör, C., Taniguchi-Ishigaki, N., Ma, H., Drung, A., Tursun, B., Ostendorff, H. P., Bossenz, M., Becker, C. G., Becker, T. and Bach, I. (2007) Proteasomal selection of multiprotein complexes recruited by LIM homeodomain transcription factors. Proc. Natl. Acad. Sci. U.S.A. 104, 15000-15005
199. Riess, N. P., Milward, K., Lee, T., Adams, M., Askham, J. M. and Morrison, E. E. (2005) Trapping of normal EB1 ligands in aggresomes formed by an EB1 deletion mutant. BMC Cell Biol. 6, 17
200. Rubinsztein, D. C. (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443, 780-786
201. Sarkar, S., Davies, J. E., Huang, Z. B., Tunnacliffe, A. and Rubinsztein, D. C. (2007) Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and α-synuclein. J. Biol. Chem. 282, 5641-5652
202. Orr, C. F., Rowe, D. B., Mizuno, Y., Mori, H. and Halliday, G. M. (2005) A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 128, 2665-2674
203. Purisai, M. G., McCormack, A. L., Cumine, S., Li, J., Isla, M. Z. and Di Monte, D. A. (2007) Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol. Dis. 25, 392-400
204. Thomas, M. P., Chartrand, K., Reynolds, A., Vitvitsky, V., Banerjee, R. and Gendelman, H. E. (2007) Ion channel blockade attenuates aggregated α-synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease. J. Neurochem. 100, 503-519
205. + regulatory T cells in an animal model of Parkinson's disease. J. Leukocyte Biol. 82, 1083-1094
206. Abou-Sleiman, P. M., Muqit, M. M. K. and Wood, N. W. (2006) Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 7, 207-219
207. Swerdlow, R. H., Parks, J. K., Cassarino, D. S., Binder, D. R., Bennett, J. P., Di Iorio, G., Golbe, L. I. and Parker, W. D. (2001) Biochemical analysis of cybrids expressing mitochondrial DNA from Contursi kindred Parkinson's subjects. Exp. Neurol. 169, 479-485
208. Keeney, P. M., Xie, J., Capaldi, R. A. and Bennett, J. P. (2006) Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci. 26, 5256-5264
209. Park, J. Y. and Chung, J. Y. (2006) PINK1 and Parkin converge in a common pathway in maintaining mitochondrial integrity and function. J. Neurogenet. 20, 197-198
210. Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M. H., Kim, J. M. and Chung, J. K. (2006) Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441, 1157-1161
211. Plun-Favreau, H., Klupsch, K., Moisoi, N., Gandhi, S., Kjaer, S., Frith, D., Harvey, K., Deas, E., Harvey, R. J., McDonald, N. et al. (2007) The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat. Cell Biol. 9, 1243-1263
212. Fritz, S., Weinbach, N. and Westermann, B. (2003) Mdm30 is an F-box protein required for maintenance of fusion-competent mitochondria in yeast. Mol. Biol. Cell 14, 2303-2313
213. Pesah, Y., Pham, T., Burgess, H., Middlebrooks, B., Verstreken, P., Zhou, Y., Harding, M., Bellen, H. and Mardon, G. (2004) Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 131, 2183-2194
214. Dauer, W. and Przedborski, S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889-909
215. Ugalde, C., Janssen, R., Smeitink, J. A. M. and Nijtmans, L. G. J. (2004) Differences in assembly or stability of complex I and other mitochondrial OXPHOS complexes in inherited complex I deficiency. Hum. Mol. Genet. 13, 659-667
216. Liu, Y. C., Fallon, L., Lashuel, H. A., Liu, Z. H. and Lansbury, P. T. (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson's disease susceptibility. Cell 111, 209-218